Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 5/20 | 0.41 |
| ▸ | CDK8 | P49336 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.38 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602518 | 1.00 | DPP4 (0.44) | DPP4FDPSMAOBTTRCCNC | |
| SCHEMBL18613637 | 0.86 | KMT2A (0.43) | FDPSTTRCCNCCDK8CA12 | |
| SCHEMBL18613639 | 0.86 | KMT2A (0.43) | FDPSTTRCCNCCDK8CA12 | |
| SCHEMBL29550737 | 0.84 | DPP4 (0.48) | DPP4FDPSMAOBTTRCCNC | |
| SCHEMBL20439711 | 0.84 | DPP4 (0.48) | DPP4FDPSMAOBTTRCCNC | |
| SCHEMBL15464600 | 0.82 | DPP4 (0.45) | DPP4FDPSMAOBTTRCCNC | |
| SCHEMBL15464599 | 0.82 | DPP4 (0.45) | DPP4FDPSMAOBTTRCCNC | |
| SCHEMBL3648457 | 0.82 | CSNK2A2 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3648459 | 0.82 | CSNK2A2 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23128180 | 0.82 | FDPS (0.41) | DPP4FDPSMAOBTTRCCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347356-B1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LTD (IN) | 2021-03-24 | — | — | EP | disclosed |
| WO-2017042834-A1 | TRICYCLIC FUSED PYRIDIN-2-ONE DERIVATIVES AND THEIR USE AS BRD4 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-03-16 | — | — | WO | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263658-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | DPP4 13/4885FDPS 3105/4885MAOB 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.